Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.Nat Rev Clin Oncol. 2014; 11: 24-37
- Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.Nat Rev Clin Oncol. 2022; 19: 91-113
- Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study.J Clin Oncol. 2016; 34: 2460-2467
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.Ann Oncol. 2019; 30: 397-404
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.Breast Cancer Res Treat. 2018; 167: 671-686
- Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study.JAMA Oncol. 2019; 5: 74-82
- Pembrolizumab for early triple-negative breast cancer.N Engl J Med. 2020; 382: 810-821
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.Lancet. 2020; 396: 1817-1828
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.Ann Oncol. 2021; 32: 1216-1235
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.Lancet. 2014; 384: 164-172
- VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC.Ann Oncol. 2021; 32: 1198-1200
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.Ann Oncol. 2019; 30: 1279-1288
- Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).J Clin Oncol. 2021; 39: 506
- Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.Ann Oncol. 2022; 33: 534-543
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.Lancet. 2020; 396: 1090-1100
- A careful reassessment of anthracycline use in curable breast cancer.NPJ Breast Cancer. 2021; 7: 134
- Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.Nat Med. 2019; 25: 1175
- Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL.in: Poster session abstracts. American Association for Cancer Research, 2020https://doi.org/10.1158/1538-7445.sabcs19-p3-09-02
- Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).J Clin Orthod. 2022; 40: 513
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.Ann Oncol. 2018; 29: 2341-2347
- CALGB 40603 (alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer.J Clin Oncol. 2022; 40: 1323-1334
- Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.Ann Oncol. 2022; 33: 384-394
- Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.JAMA Oncol. 2020; 6: 676-684
- Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.J Clin Oncol. 2022; 40: 503
- Adjuvant capecitabine for breast cancer after preoperative chemotherapy.N Engl J Med. 2017; 376: 2147-2159
- VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer.Ann Oncol. 2022; 33: 566-568
- TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.J Clin Oncol. 2018; 36: 1011
- Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts.in: Ongoing clinical trials. American Association for Cancer Research, 2019https://doi.org/10.1158/1538-7445.sabcs18-ot3-05-03
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.Lancet Oncol. 2018; 19: 40-50
- Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy.J Clin Oncol. 2022; 40: 2361-2374
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.Ann Oncol. 2020; 31: 1216-1222
- LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial.Ann Oncol. 2020; 31: S1145-S1146
- Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial.Cancer Res. 2022; 82: 07-12
- Abstract PD5-05: Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial.in: Poster discussion abstracts. American Association for Cancer Research, 2019https://doi.org/10.1158/1538-7445.sabcs18-pd5-05
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.Lancet Oncol. 2021; 22: 499-511
- Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase Ib/II study.Clin Cancer Res. 2021; 27: 3061-3068
- Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer.in: General session abstracts. American Association for Cancer Research, 2021https://doi.org/10.1158/1538-7445.sabcs20-gs3-01
- Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.N Engl J Med. 2018; 379: 2108-2121
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.Ann Oncol. 2021; 32: 983-993
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.Ann Oncol. 2021; 32: 994-1004
- Nivolumab and ipilimumab in advanced melanoma.N Engl J Med. 2017; 377: 2503-2504
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.Lancet Oncol. 2019; 20: 1239-1251
- Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer.J Clin Oncol. 2020; 38: 1505-1517
- A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407.J Thorac Oncol. 2020; 15: 1657-1669
- Considerations for treatment duration in responders to immune checkpoint inhibitors.J Immunother Cancer. 2021; 9: e001901
- Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.Nat Med. 2021; 27: 250-255
- PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer.J Natl Cancer Inst. 2021; 113: 1733-1743
- Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.J Immunother Cancer. 2020; 8: e001558
- Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: Biomarker evaluation of the IMpassion130 study.J Natl Cancer Inst. 2021; 113: 1005-1016
- Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer.Clin Cancer Res. 2020; 26: 2565-2572
- Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC).Cancer Res. 2022; 82 (GS2-10)
- Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: Results from the targeted agent and profiling utilization registry (TAPUR) study.J Clin Oncol. 2021; 39: 2443-2451
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2018; 29: iv264-iv266
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Ann Oncol. 2021; 32: 229-239
- Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response.in: Poster session abstracts. American Association for Cancer Research, 2020https://doi.org/10.1158/1538-7445.sabcs19-p3-09-15
- Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).J Clin Oncol. 2021; 39: TPS1102
- Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).J Clin Oncol. 2021; 39: TPS1106
- Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR).in: Ongoing clinical trials abstracts. American Association for Cancer Research, 2021https://doi.org/10.1158/1538-7445.sabcs20-ot-03-06
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
